Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
The cost-effectiveness of bazedoxifene was compared to placebo in France, Germany, Italy, Spain, Sweden and the UK from a healthcare perspective using FRAX® for both fracture risks and for treatment efficacy. Cost/QALY differences were explained to a large extent by differences in fracture risk.
In cost-effectiveness modelling of osteoporosis treatments, the fracture risk has traditionally been calculated with risk adjustments based on age, bone mineral density and prior fracture. However, knowledge of additional clinical risk factors contributes to fracture risk assessment as demonstrated by the FRAX® tool. Bazedoxifene, a new selective estrogen receptor modulator for the treatment and prevention of osteoporosis, has been shown in a phase III clinical trial to reduce the risk of osteoporotic fractures in women. In an analysis using FRAX®, the efficacy of bazedoxifene was greater in patients with higher fracture risk.
The aim of this study was to evaluate the cost-effectiveness of bazedoxifene compared to placebo in France, Germany, Italy, Spain, Sweden and the UK from a healthcare perspective using FRAX®. A Markov cohort model was adapted to incorporate the FRAX® risk factors. FRAX® produces relative risks for hip fractures and major osteoporotic fractures. Patients were given a 5-year intervention, reducing the risk of fractures in a risk-dependent manner. The effect of treatment on fractures was assumed to decline linearly over 5 years after the intervention.
There are large cost/quality-adjusted life year variations between countries in the European setting studied. The base case values ranged from cost saving (Sweden) to EUR 105,450 (Spain) in 70-year-old women with a T-score of −2.5 SD and a prior fracture.
Bazedoxifene can be a cost-effective treatment for postmenopausal osteoporosis. The variability between countries was explained to a large extent by differences in fracture risk, and the estimated cost-effectiveness was highly dependent on the population’s FRAX®-estimated probability of major osteoporotic fracture.
- Cooper C, Atkinson EJ, Jacobsen SJ, O’Fallon WM, Melton LJ 3rd (1993) Population-based study of survival after osteoporotic fractures. Am J Epidemiol 137:1001–1005
- Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta JR, de Villiers TJ, Constantine GD, Chines AA (2008) Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 23:1923–1934 CrossRef
- McCloskey E, Johansson H, Oden A, Kanis JA (2009) Bazedoxifene reduces all clinical fractures and morphometric vertebral fractures in postmenopausal women at increased fracture risk assessed with FRAX®. Osteoporos Int 20(Suppl 2):199–200
- Kanis JA, Johansson H, Oden A, McCloskey EV (2009) Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone 44:1049–1054 CrossRef
- Strom O, Borgstrom F, Sen SS, Boonen S, Haentjens P, Johnell O, Kanis JA (2007) Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries—an economic evaluation based on the fracture intervention trial. Osteoporos Int 18:1047–1061 CrossRef
- Ström O, Coelho J, Borgstrom F, McCloskey E, Odén A, Johansson H, Kanis J (2009) Cost-effectiveness of bazedoxifene in the UK and Sweden incorporating the FRAX-algorithm Oral presentation (OC27). ECCEO, Athens
- Borgstrom F, Zethraeus N (2003) Economic assessment based on a clinical study of risedronate. Fracture prevention in elderly women with osteoporosis is cost-effective. Lakartidningen 100:36–40
- Borgstrom F, Johnell O, Kanis JA, Oden A, Sykes D, Jonsson B (2004) Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics 22:1153–1165 CrossRef
- Kanis JA, Borgstrom F, Johnell O, Oden A, Sykes D, Jonsson B (2005) Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporos Int 16:15–25 CrossRef
- Borgstrom F, Zethraeus N, Johnell O, Lidgren L, Ponzer S, Svensson O, Abdon P, Ornstein E, Lunsjo K, Thorngren KG, Sernbo I, Rehnberg C, Jonsson B (2006) Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos Int 17:637–650 CrossRef
- Ström O, Borgstrom F, Zethraeus N, Johnell O, Lidgren L, Ponzer S, Svensson O, Abdon P, Ornstein E, Ceder L, Thorngren KG, Sernbo I, Jonsson B (2008) Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden. Acta Orthop 79:269–280 CrossRef
- Kanis JA, Johnell O, Oden A, Jonsson B, Dawson A, Dere W (2000) Risk of hip fracture derived from relative risks: an analysis applied to the population of Sweden. Osteoporos Int 11:120–127 CrossRef
- De Laet CE, van Hout BA, Burger H, Hofman A, Pols HA (1997) Bone density and risk of hip fracture in men and women: cross sectional analysis. Br Med J 315:221–225
- Kanis JA, Johansson H, Oden A, McCloskey EV (2009) Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX((R)). Bone 44:1049–1054
- McCloskey E, Johansson H, Oden A, Kanis J (2009) Bazedoxifen reduces all clinical fractures and morphometric vertebral fractures in postmenopausal women at increased fracture risk assessed with FRAX®. Oral presentation (OC32), ECCEO, Athens
- EMEA (2009) Committee for medicinal products for human use—summary of positive opinion for Conbriza. London, 19 February
- Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765 CrossRef
- Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85:4118–4124 CrossRef
- Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922–928 CrossRef
- Seeman E, Compston J, Adachi J, Brandi ML, Cooper C, Dawson-Hughes B, Jonsson B, Pols H, Cramer JA (2007) Non-compliance: the Achilles’ heel of anti-fracture efficacy. Osteoporos Int 18:711–719 CrossRef
- (2008) Final appraisal determination. Alendronate, etidronate, risedronate, raloxifene, and strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. National Institute for Health and Clinical Excellence, London.
- (2008) Final appraisal determination. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. National Institute for Health and Clinical Excellence, London.
- Kanis JA, Brazier JE, Stevenson M, Calvert NW, Lloyd Jones M (2002) Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 6:1–146
- Elffors I, Allander E, Kanis JA, Gullberg B, Johnell O, Dequeker J, Dilsen G, Gennari C, Lopes Vaz AA, Lyritis G et al (1994) The variable incidence of hip fracture in southern Europe: the MEDOS Study. Osteoporos Int 4:253–263 CrossRef
- Brecht JG, Kruse HP, Mohrke W, Oestreich A, Huppertz E (2004) Health-economic comparison of three recommended drugs for the treatment of osteoporosis. Int J Clin Pharmacol Res 24:1–10
- Singer BR, McLauchlan GJ, Robinson CM, Christie J (1998) Epidemiology of fractures in 15,000 adults: the influence of age and gender. J Bone Joint Surg Br 80:243–248 CrossRef
- Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A, De Laet C, Jonsson B (2000) Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 11:669–674 CrossRef
- Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12:417–427 CrossRef
- Silverstein MD, Heit JA, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ 3rd (1998) Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 158:585–593 CrossRef
- Centre for Epidemiology at the National Board of Health and Welfare, Sweden.
- Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAXTM and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385–397 CrossRef
- Lothgren M, Zethraeus N (2000) Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Econ 9:623–630 CrossRef
- Jonsson B, Christiansen C, Johnell O, Hedbrandt J, Karlsson G (1996) Cost-effectiveness of fracture prevention in established osteoporosis. Scand J Rheumatol Suppl 103:30–38 CrossRef
- Borgstrom F, Carlsson A, Sintonen H, Boonen S, Haentjens P, Burge R, Johnell O, Jonsson B, Kanis JA (2006) The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective. Osteoporos Int 17:996–1007 CrossRef
- Borgstrom F, Jonsson B, Strom O, Kanis JA (2006) An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials. Osteoporos Int 17:1781–1793 CrossRef
- Kind P, Dolan P, Gudex C, Williams A (1998) Variations in population health status: results from a United Kingdom national questionnaire survey. Br Med J 316:736–741
- Burstrom K, Johannesson M, Diderichsen F (2001) Swedish population health-related quality of life results using the EQ-5D. Qual Life Res 10:621–635 CrossRef
- National Osteoporosis Foundation (1998). Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effective analysis. Osteoporos Int 8(Suppl 4):1–88.
- Oleksik A, Lips P, Dawson A, Minshall ME, Shen W, Cooper C, Kanis J (2000) Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res 15:1384–1392 CrossRef
- Sobocki P, Lekander I, Borgstrom F, Strom O, Runeson B (2007) The economic burden of depression in Sweden from 1997 to 2005. Eur Psychiatry 22:146–152 CrossRef
- Zethraeus N, Borgstrom F, Jonsson B, Kanis J (2005) Reassessment of the cost-effectiveness of hormone replacement therapy in Sweden: results based on the Women’s Health Initiative randomized controlled trial. Int J Technol Assess Health Care 21:433–441 CrossRef
- Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D (2000) Risk of mortality following clinical fractures. Osteoporos Int 11:556–561 CrossRef
- Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353:878–882 CrossRef
- Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301:513–521 CrossRef
- Oden A, Dawson A, Dere W, Johnell O, Jonsson B, Kanis JA (1998) Lifetime risk of hip fractures is underestimated. Osteoporos Int 8:599–603 CrossRef
- Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, De Laet C, Jonsson B (2004) Mortality after osteoporotic fractures. Osteoporos Int 15:38–42 CrossRef
- Poor G, Atkinson EJ, O’Fallon WM, Melton LJ, 3rd (1995) Determinants of reduced survival following hip fractures in men. Clin Orthop Relat Res 260–265
- Kanis J, Johnell O, Odén A, Laet CD, Jonsson B, Oglesby A (2002) Excess mortality after vertebral fracture. WHO Collaborating Centre for Metabolic Bone Diseases, Sheffield, UK.
- Parker MJ, Anand JK (1991) What is the true mortality of hip fractures? Public Health 105:443–446 CrossRef
- Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK (2003) The components of excess mortality after hip fracture. Bone 32:468–473 CrossRef
- NICE (2008) Osteoporosis—secondary prevention including strontium ranelate: appraisal consultation document. www.nice.org.uk
- Vestergaard P, Rejnmark L, Mosekilde L (2007) Increased mortality in patients with a hip fracture—effect of pre-morbid conditions and post-fracture complications. Osteoporos Int 18:1583–1593 CrossRef
- Kearon C (2003) Natural history of venous thromboembolism. Circulation 107:I22–I30
- Committee for medicinal products for human use (CHMP). Guidelines on the evaluation of medicinal products in the treatment of primary osteoporosis. (Lond 16 Nov 2006 CPMP/EWP/552/95 Rev.2)
- Kanis JA, Adams J, Borgstrom F, Cooper C, Jonsson B, Preedy D, Selby P, Compston J (2008) The cost-effectiveness of alendronate in the management of osteoporosis. Bone 42:4–15 CrossRef
- van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 39:1383–1389 CrossRef
- Kanis JA, Johansson H, Johnell O, Oden A, De Laet C, Eisman JA, Pols H, Tenenhouse A (2005) Alcohol intake as a risk factor for fracture. Osteoporos Int 16:737–742 CrossRef
- Delmas PD, Genant HK, Crans GG, Stock JL, Wong M, Siris E, Adachi JD (2003) Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 33:522–532 CrossRef
- NICE (2008) Guide to the methods of technology appraisal. http://wwwniceorguk/media/B52/A7/TAMethodsGuideUpdatedJune2008pdf.
- Borgström F, Johnell O, Kanis J, Jönsson B, Rehnberg C (2006) At what risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis. Osteoporos Int 17:1459–1471
- Stevenson M, Davis S (2006) Analyses of the cost-effectiveness of pooled alendronate and risedronate, compared with strontium ranelate, raloxifene, etidronate and teriparatide. School of Health and Related Research, University of Sheffield. Sheffield
- Visentin P, Ciravegna R, Fabris F (1997) Estimating the cost per avoided hip fracture by osteoporosis treatment in Italy. Maturitas 26:185–192 CrossRef
- Zethraeus N, Strom O, Borgstrom F (2006) What is the risk of institutionalization after hip fracture? Osteoporos Int 17(Suppl 1):57–58
- Gordois A, Posnett J, Borris L, Bossuyt P, Jonsson B, Levy E, de Pouvourville G (2003) The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery. J Thromb Haemost 1:2167–2174 CrossRef
- Kobelt G, Berg J, Lindgren P, Izquierdo G, Sanchez-Solino O, Perez-Miranda J, Casado MA (2006) Costs and quality of life of multiple sclerosis in Spain. Eur J Health Econ 7(Suppl 2):S65–S74 CrossRef
- Stockholms stads budgetavräkning (2003) [online]. [cited 2004-12-20]. Available from: www.stockholm.se/files/71600-71699/file_71645.pdf
- Strom O, Borgstrom F, Sen SS, Boonen S, Haentjens P, Johnell O, Kanis JA (2007) Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries--an economic evaluation based on the fracture intervention trial. Osteoporos Int 18:1047–1061
- L’assurance maladie en ligne 2004.
- Lordick F, Ehlken B, Ihbe-Heffinger A, Berger K, Krobot KJ, Pellissier J, Davies G, Deuson R (2007) Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany. Eur J Cancer 43:299–307 CrossRef
- Capri S, Perlini S (2005) Cost-effectiveness in Italy of preventive treatment with ramipril in patients at high risk of cardiovascular events. Curr Med Res Opin 21:913–921 CrossRef
- Curtis L, Unit Costs of Health and Social Care (2008) [online]. [cited 2009-02-03]. Personal Social Services Research Unit: University of Kent, Available from: http://www.pssru.ac.uk/uc/uc.htm
- Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective
Volume 22, Issue 3 , pp 955-965
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Clinical risk factor
- Industry Sectors
- Author Affiliations
- 1. i3 Innovus, Stockholm, Sweden
- 2. LIME/MMC, Karolinska Institutet, Stockholm, Sweden
- 5. Klarabergsviadukten 90, hus D, 2 tr, 111 64, Stockholm, Sweden
- 3. Osteoporosis Centre, Northern General Hospital, Sheffield, UK
- 4. WHO Collaborating Centre, University of Sheffield, Sheffield, UK